论文信息 - Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. - 字舞流文

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

P. Richardson | S. Ansell | A. Dispenzieri | D. DeAngelo | S. Treon | I. Ghobrial | C. Reeder | M. Gertz | T. Witzig | M. Lacy | B. Laplant | S. Hayman | B. Harris | J. Camoriano | M. Rourke | R. Leduc | L. Bergsagel | S. Chuma | K. Anderson